Mylan Rolls Out Generic Version Of Epivir Tablets
Mylan Inc (NASDAQ: MYL) has rolled out the generic version of ViiV Healthcare's Epivir tablets in the United States, according to a new press statement. The tablet, Lamivudine, would be available in 150 mg and 300 mg in the market. The company said that the FDA has given its final approval for its ANDA for the product. The tablet is meant for treating HIV – 1 infection.
Mylan indicated that the Lamivudine drug had sales of about $27.1 million in the United States for the year ended 2015.
The company said that it has 265 ANDAs pending before the regulator for approval. That accounted for $110.3 billion brand sales on an annualized basis, Mylan said, quoting IMS Health. The drug maker said that forty-eight of them were the first-to-file opportunities and represented $38.3 billion brand sales on an annualized basis.
On Wednesday, Mylan shares rose by 4.5 percent.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.